Moloney Securities Asset Management LLC Purchases 56,100 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL)

Moloney Securities Asset Management LLC boosted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 177.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 87,799 shares of the company’s stock after buying an additional 56,100 shares during the period. Moloney Securities Asset Management LLC’s holdings in Precision BioSciences were worth $335,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC raised its holdings in shares of Precision BioSciences by 40.7% in the 3rd quarter. Geode Capital Management LLC now owns 65,974 shares of the company’s stock valued at $591,000 after acquiring an additional 19,088 shares in the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Precision BioSciences in a report on Friday, January 10th. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target for the company in a research note on Friday, January 10th.

Precision BioSciences Trading Up 1.9 %

Shares of DTIL stock opened at $4.79 on Tuesday. The business has a 50-day moving average price of $5.02 and a two-hundred day moving average price of $7.58. Precision BioSciences, Inc. has a 12-month low of $3.61 and a 12-month high of $19.43. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The firm has a market cap of $36.74 million, a P/E ratio of 79.85 and a beta of 1.51.

Insider Buying and Selling

In other Precision BioSciences news, insider J. Jefferson Smith sold 10,287 shares of Precision BioSciences stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $4.79, for a total transaction of $49,274.73. Following the transaction, the insider now directly owns 87,440 shares of the company’s stock, valued at approximately $418,837.60. This trade represents a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael Amoroso sold 36,838 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total transaction of $172,033.46. Following the completion of the sale, the chief executive officer now directly owns 107,087 shares of the company’s stock, valued at $500,096.29. This trade represents a 25.60 % decrease in their position. The disclosure for this sale can be found here. Insiders bought 8,734 shares of company stock worth $39,946 in the last quarter. 4.00% of the stock is owned by insiders.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.